Disease or Syndrome – Page 71

Axplora Invests €50M in GLP-1 Manufacturing Expansion at Mourenx, France

9 months ago talkbio0Tagged alpha 1-antitrypsin, Axplora, biology (field), CDMO, Chromatography, Diabetes, expansion, France, Glucagon-Like Peptide 1, Manufacturing, Mourenx, Obesity, production

Axplora, GLP-1, manufacturing expansion, Mourenx, France, CDMO, API production, chromatography, diabetes, obesity, biologic therapies

AnaptysBio’s Rosnilimab Shows Promising Results in Phase 2b Rheumatoid Arthritis Trial, Driving Stock Surge

9 months ago talkbio0Tagged AnaptysBio, Immunology, Increase, Prices, RENOIR, Rheumatoid Arthritis, Rosnilimab, Treatment Effectiveness

AnaptysBio, rosnilimab, rheumatoid arthritis, Phase 2b trial, RENOIR study, clinical efficacy, stock price increase, immunology therapeutics

Biogen Secures $250 Million R&D Funding from Royalty Pharma for Lupus Drug Litifilimab

9 months ago talkbio0Tagged Biogen, Litifilimab, Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lupus Vulgaris, Pharma, Phase 3, Phase 3 trials, R&D, Royalty

Biogen, Royalty Pharma, litifilimab, lupus, R&D funding, Phase 3 trials, systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE)

Royalty Pharma Invests $250M in Biogen’s Late-Stage Lupus Treatment

9 months ago talkbio0Tagged Biogen, Litifilimab, Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lupus Vulgaris, Pharma, Phase 3 trials, R&D, Royalty

Biogen, Royalty Pharma, litifilimab, lupus, Phase 3 trials, R&D funding, systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE)

AnaptysBio’s Rosnilimab Shows Promising Results in Phase 2b Rheumatoid Arthritis Trial

9 months ago talkbio0Tagged Agonist, AnaptysBio, Autoimmune Diseases, Immunoregulation, PDCD1 gene, Rheumatoid Arthritis, Rosnilimab

Rosnilimab, PD-1 agonist, rheumatoid arthritis, Phase 2b trial, immune modulation, AnaptysBio, autoimmune disease

Voyager Therapeutics Halts ALS Gene Therapy Development Due to Off-Target Effects

9 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Capsid, Cu-Zn Superoxide Dismutase, Drug Development, Effect, gene therapy, off-target, payload, Preclinical, RNA, Small Interfering, Tracer, VY9323

SOD1 ALS gene therapy, Off-target effects, VY9323, siRNA payload, TRACER capsid, Preclinical data, Drug development delay

Novartis Acquires Anthos Therapeutics for $925M, Regaining Control of Promising Anticoagulant Abelacimab

9 months ago talkbio0Tagged abelacimab, Acquisition, Anthos, Anticoagulants, Atrial Fibrillation, cardiovascular pipeline, Cerebrovascular accident, Factor XI antibody, Novartis

Novartis, Anthos Therapeutics, acquisition, abelacimab, anticoagulant, Factor XI inhibitor, atrial fibrillation, stroke prevention, cardiovascular pipeline

Merck KGaA in Advanced Talks to Acquire SpringWorks Therapeutics, Bolstering Oncology Portfolio

9 months ago talkbio0Tagged Acquisition, Drug Industry, Gomekli, Merck KGaA, Neoplasms, Ogsiveo, SpringWorks

Merck KGaA, SpringWorks Therapeutics, acquisition, oncology, rare diseases, Ogsiveo, Gomekli, pharmaceutical industry

Merck KGaA in Advanced Negotiations to Acquire SpringWorks Therapeutics

9 months ago talkbio0Tagged Acquisition, biopharmaceutical industry, cancer treatments, Does speak, Merck KGaA, Ogsiveo, SpringWorks

Merck KGaA, SpringWorks Therapeutics, acquisition talks, biopharmaceutical industry, rare diseases, cancer treatments, Ogsiveo

Boehringer Ingelheim’s Nerandomilast Achieves Second Phase III Success in Pulmonary Fibrosis Treatment

9 months ago talkbio0Tagged Boehringer, FIBRONEER-ILD, Force, Idiopathic Pulmonary Fibrosis, Ingelheim, nerandomilast, Phase 3 Clinical Trials, Progressive, Pulmonary Fibrosis, Respiratory physiology, Vital capacity

Nerandomilast, Boehringer Ingelheim, Phase III trial, FIBRONEER-ILD, progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, lung function, forced vital capacity